 |
|
|
| |
No Impact of RASs on the High Efficacy of BEM and RZR in Combination: Resistance Analysis from a Phase 2 Study in HCV-infected Patients
|
| |
| |
AASLD 2025 Nov 7-11 Wash DC
Qi Huang, Dawei Cai, Shannan Lynch, Keith Pietropaolo, Xiao-Jian Zhou, Sergey Izmailyan, Arantxa Horga, Janet M. J. Hammond, Nancy G. B. Agrawal and Jean-Pierre Sommadossi
Atea Pharmaceuticals, Boston, USA
|
| |
|
|
|
|
|
